ARVN
ARVINAS, INC.
NASDAQ · Healthcare · Biotechnology · US
$8.29
−0.24%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.87
- Revenue estimate
- $16.8M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $2.58
- EPS estimate
- -$0.37
- Revenue actual
- $249.7M
- Revenue estimate
- $60.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +182.7%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $15
- PT range
- $11 – $21
- Analysts
- 6
4 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.37 | $2.58 | Beat 789.64% | $249.7M |
| May 12, 2026 | -$0.95 | -$0.90 | Beat 5.26% | $15.6M |
| Feb 24, 2026 | -$0.55 | -$1.10 | Miss -100.00% | $9.5M |
| Nov 5, 2025 | -$0.75 | -$0.48 | Beat 36.00% | $41.9M |
| Aug 6, 2025 | -$0.87 | -$0.84 | Beat 3.45% | $22.4M |
| May 1, 2025 | -$0.86 | $1.14 | Beat 232.56% | $188.8M |
| Feb 27, 2024 | -$1.33 | -$2.53 | Miss -90.23% | $43.1M |
| May 5, 2023 | -$1.46 | -$1.54 | Miss -5.48% | $32.5M |
| Feb 23, 2023 | -$1.04 | -$1.56 | Miss -50.00% | $38.0M |
| Aug 4, 2022 | -$1.02 | -$1.32 | Miss -29.41% | $31.3M |
| May 5, 2022 | -$0.85 | -$1.20 | Miss -41.18% | $24.2M |
| Feb 28, 2022 | -$0.78 | -$1.00 | Miss -28.21% | $26.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026